Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial

BACKGROUND: Antiplatelet treatment is an important component in optimizing the clinical outcomes after percutaneous coronary intervention (PCI) especially in patients with acute coronary syndrome (ACS). Prasugrel, which is a new P2Y12 inhibitor, has been confirmed as efficacious in a large trial in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Joo Myung, Jung, Ji-Hyun, Park, Kyung Woo, Shin, Eun-Seok, Oh, Seok Kyu, Bae, Jang-Whan, Rhew, Jay Young, Lee, Namho, Kim, Dong-Bin, Kim, Ung, Han, Jung-Kyu, Lee, Sang Eun, Yang, Han-Mo, Kang, Hyun-Jae, Koo, Bon-Kwon, Kim, Sanghyun, Cho, Yun Kyeong, Shin, Won-Yong, Lim, Young-Hyo, Rha, Seung-Woon, Kim, Seok-Yeon, Lee, Sung Yun, Kim, Young-Dae, Chae, In-Ho, Cha, Kwang Soo, Kim, Hyo-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570043/
https://www.ncbi.nlm.nih.gov/pubmed/26374625
http://dx.doi.org/10.1186/s13063-015-0925-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570043/
https://www.ncbi.nlm.nih.gov/pubmed/26374625
http://dx.doi.org/10.1186/s13063-015-0925-5

Ejemplares similares